This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stock Mailbag: NuPathe

Jeff S. emails, "Northwest Biotherapeutics(NWBO.OB) looks to be lifting their profile following survival mode through the recession. All the chips seem to be on the table, banking on DCVax-Brain achieving FDA clearance following reconfigured phase II for gliobastoma multiforme. Other news seems superficial to me, with only this fact mattering. But certain metrics show the trial is enrolling well. Is this a realistic jump (over phase III)? And if so, could a long-term investor see tempered returns in the next 24 months?"

Let me start on Northwest Biotherapeutics by quoting myself from a Feb. 18 Mailbag, which I wrote after I saw the company present at the BIO CEO Conference in New York.

"I saw some bad stuff Monday and Tuesday. Topping the garbage list was Northwest Biotherapeutics -- easily the worst and most laughable presentation I saw at the conference. I almost fell off my chair when Northwest chief Linda Powers showed slides with Kaplan-Meyer survival curves demonstrating a "survival benefit" for the company's DCVax cancer immunotherapy over historical data culled from previously published clinical studies. Heck, Powers even attached a statistically significant p value to this pseudo-scientific nonsense. The entire Northwest presentation was appalling."

I hope my contempt for Northwest Biotherapeutics is clear. Just like you wouldn't invest in a company that manipulates accounting rules to make its financial results look better than they really are, you also shouldn't invest in a drug company that abuses biostatistics to make its cancer immunotherapy (or any drug) appear more effective than it is. The latter is what Northwest Biotherapeutics is doing with data from two phase I studies of DCVax-Brain which enrolled 29 patients from the same hospital.

You cannot make a survival benefit claim from a single-arm study, i.e., a study without a comparator arm! This is an iron-clad rule. No exceptions.

Be very skeptical of any company trying to convince you that its experimental drug is helping patient live longer based on a single-arm study. Be skeptical, insulted and angry when a company serves up this B.S. claim with a statistically significant p value.

Via Twitter, @ssekhar asks, "Hey Adam, any thoughts on potential for a YM BioSciences(YMI) partnership with Big Pharma? Too risky until their phase II reads out?"

Agreed. I'll be shocked if YM lands a development/marketing partner for its myelofibrosis drug CYT387 until after data from the ongoing phase II study is presented at the American Society of Hematology annual meeting in December. These data should help clarify the controversy over '387's ability to correct anemia in myelofibrosis patients, as well as provide more color on the drug's biggest side effect risk, peripheral neuropathy.

Given the big run-up in YM's stock price leading into the ASCO annual meeting earlier this month, I was expecting the stock to sell off some after the meeting ended. I wasn't expecting YM shares to lose nearly all the gains made in the pre-ASCO run, however, which is what's happened. [A lousy market overall hasn't helped.]
3 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
PATH $0.00 0.00%
EXEL $3.76 0.00%
INCY $104.21 0.00%
TKMR $11.86 0.00%
AAPL $125.42 0.00%

Markets

DOW 17,619.51 +23.16 0.13%
S&P 500 2,063.11 +5.48 0.27%
NASDAQ 4,986.8670 +28.3990 0.57%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs